Profil Tumor Infiltrating Lymphocytes Dan Mitotic Index Pada Melanoma Maligna Di RSUP H Adam Malik Medan Tahun 2011-2015
43
DAFTAR PUSTAKA
Attis, M.G., Vollmer, R.T., 2007. Mitotic Rate in Melanoma a Reexamination.
Am
J
Clin
Pathol
2007
127:380-384.
doi:
10.1309/LB7RTC61B7LC6HJ6.
Azimi, F., Scolyer, R.A., Rumcheva, P,. et al., 2012. Tumor-Infiltrating
Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph
Node Status and Survival in Patients with Cutaneous Melanoma.
Journal of Clinical Oncology 30(21): 2678-2683.
Balch, C.M., Gershenwald, J.E., Soong, S., et al., 2009. Final Version of 2009
AJCC Melanoma Staging and Classification. Journal of Clinical
Oncology 27(36): 6199-6206.
Balch, C.M., Gershenwald, J.E., Soong, S., et al., 2010. Multivariate Analysis of
Prognostic Factors Among 2,313 Patients With Stage III Melanoma:
Comparison of Nodal Micrometastases Versus Macrometastases.
Journal of Clinical Oncology 28(14): 2452-2459.
Bandarchi, B., Ma, L., Navab, R., et al., 2010. From Melanocyte to Metastatic
Malignant
Melanoma.
Dermatology
Research
and
Practice.
doi:10.1155/2010/583748
Bogunovic, D., O’Neill,D.W., Levy, I.B., et al., 2009. Immune Profile and
Mitotic Index of Metastatic Melanoma Lesions Enhance Clinical
Staging in Predicting Patient Survival. PNAS 106(48): 20429-20434.
Busam, K. J., Antonescu, C. R., Marghoob, A. A. et al., 2001. Histologi
Classification
of
Tumor-Infiltrating
Lymphocytes
in
Primary
Cutaneous Malignant Melanoma. Am J Clin Pathol 2001;115: 856860.
Chan, C., Greenbaum, A., 2013. Skin and Subcutaneous Tissue. In: Williams,
N.S., Bulstrode, C.J.K., O’Connel, P.R., 2013. Bailey & Love’s Short
Practice of Surgery, 26th ed. Boca Raton: Taylor & Francis Group,
CRC Press: 594-598.
44
Chung, K.T., Nilson, E.H., Case, M.J. et al., 1973. Estimation of Growth Rate
from the Mitotic Index. In: Thomas, N.E., Kricker, A., Waxweiler,
W.T. et al., 2014. Comparison of Clinicopathologic Features and
Survival
of
Histopathologically
Amelanotic
and
Pigmented
Melanomas: A Population-Based Study. JAMA Dermatol 150(12):
1306-1314.
de Vries, E., Bray, F., Coebergh, J.W., et al., 2006. Melanocytic tumours. In:
LeBoit, P.E., Burg, G., Weedon, D., et al., 2006. Pathology &
Genetics Skin Tumours. Lyon: International Agency for Research on
Cancer Press: 52-65.
de Vries, E., Nijsten, T.E.C., Visser, O., et al., 2007. Superior Survival of Females
Among 10 538 Dutch Melanoma Patients Is Independent of Breslow
Thickness, Histologic Type and Tumor Site. Annals of Oncology.
doi:10.1093/annonc/mdm498.
Donizy, P., Zietek, M., Leskiewicz, M., et al., 2015. High Percentage of ADAM10 Positive Melanoma Cells Correlates with Paucity of TumorInfiltrating Lymphocytes but Does Not Predict Prognosis in
Cutaneous Melanoma Patients. Analytical Cellular Pathology.
http://dx.doi.org/10.1155/2015/975436.
Forman, D., Bray, F., Brewster, D.H., et al., 2014. Cancer Incidence in Five
Continents vol. X. Lyon: International Agency for Research on
Cancer (164).
Garbe, C., Büttner, P., Bertz, J., et al., 1995. Primary Cutaneous Melanoma:
Prognostic
Classification
of
Anatomic
Location.
Cancer
1995(75):2492-8.
GLOBOCAN, 2012. Estimated Cancer Incidence, Mortality, and Prevalence
Worldwide in 2012. International Agency for Research on Cancer .
Available
at
45
http://globocan.iarc.fr/Pages/fact_sheets_population.aspx?country=36
0 [Accessed June 22th 2015]
Goldstein, B.G., and Goldstein, A.O., 2001. Diagnosis and Management of
Malignant Melanoma. American Family Physician 63(7): 1359-1386.
Hale, C.S., Qian, M., Ma, M.W. et al., 2013. Mitotic Rate in Melanoma:
Prognostic Value of Immunostaining and Computer-Assisted Image
Analysis. Am J Surg Pathol 37(6): 882–889.
Herbst, M.C., 2014. Fact Sheet on Malignant Melanoma. Cancer Association of
South Africa : 1-15.
Hernberg, M., Turunen, J.P., Muhonen, T. et al., 1997. Tumor Infiltrating
Lymphocytes
in
Metastatic
Melanomas
Receiving
Chemoimmunotherapy. In: Rao, U.M.N., Lee, S.J., Luo, W., et al.,
2010. Presence of Tumor-Infiltrating Lymphocytes and a Dominant
Nodule Within Primary Melanoma Are Prognostic Factors for
Relapse-Free Survival of Patients With Thick (T4) Primary
Melanoma. Am J Clin Pathol 133: 646-653.
Holterhues, C., 2011. Burden of Melanoma. Rotterdam: Optima Grafische
Communicatie: 7-10.
Houghton, A.N., Guevara-patiño, J.A., 2004. Immune Recognition of Self in
Immunity Against Cancer. J. Clin. Invest. 114: 468–471 (2004).
doi:10.1172/JCI200422685.
Junowo, Juniarto, A.Z., 2000. Biologi Sel. Jakarta: Penerbit Buku Kedokteran
EGC: 75-83.
King, R.J.B., 2000. Cancer Biology, 2nd ed. Pearson Education Limited: 58-68,
148-157.
Knezevich, S.R., Barnhill, R.L., Elder, D.E., et al., 2014. Variability in Mitotic
Figures in Serial Sections of Thin Melanomas. American Academy of
Dermatology. J Am Acad Dermatol 71(6): 1204–1211.
46
Larsen, T.E., Grude, T.H., 1978. A Retrospective Histological Study of 669 Cases
of Primary Cutaneous Malignant Melanoma in Clinical Stage I: 3, The
Relationship Between the Tumor-Associated Lymphocyte Infiltration
and Age and Sex, Tumor Cell Type, Pigmentation, Cellular Atypia,
Mitotic Count, Depth of Invasion, Ulceration, Tumor Type and
Prognosis. In: Taylor, R.C., Patel, A., Panageas, K.S., et al., 2007.
Tumor-infiltrating Lymphocytes Predict Sentinel Lymph Node
Positivity in Patients With Cutaneous Melanoma. J Clin Oncol
25:869-875. DOI: 10.1200/JCO.2006.08.9755.
Lee, S.J., Lim, H.J., Choi, Y.H., et al., 2013. The Clinical Significance of TumorInfiltrating Lymphocytes and Microscopic Satellites in Acral
Melanoma in a Korean Population. Ann Dermatol 25(1):61-66.
http://dx.doi.org/10.5021/ad.2013.25.1.61.
Ma, M.W., Medicherla, R.C., Qian, M., et al., 2012. Immune Response in
Melanoma: an In-Depth Analysis of The Primary Tumor and
Corresponding Sentinel Lymph Node. National Institute of Health.
doi:10.1038/modpathol.2012.43.
MacKie, R.M., Hauschild, A., and Eggermont, A.M.M., 2009. Epidemiology of
Invasive Cutaneous Melanoma. Annals of Oncology 20(6): vi1–vi7.
Maio, M., 2012. Melanoma as a Model Tumour for Immuno-Oncology. Annals of
Oncology 23 (Supplement 8): viii 10. doi:10.1093/annonc/mds257.
McCourt, C., Dolaé, O., and Gormley, G., 2014. Malignant Melanoma: A
Pictorial Review. Ulster Med J 83(2): 103-110.
Miller, A.J., and Mihm, M.C., 2006. Mechanisms of Disease Melanoma. N Engl J
Med 355: 51-65.
Nagore, E., Oliver, V., Botella-Estrada, R., et al., 2006. Clinicophatological
Analysis of 1571 Cutaneous Malignant Melanoma in Valencia, Spain:
Factors Related to Tumour Thickness. Acta Derm Venerol 2006
(86):50-56. DOI: 10.2340/00015555-0004.
47
Nagorsen, D., Scheibenbogen, C., Marincola, F.M., et al., 2003. Natural T Cell
Immunity Against Cancer. American Association for Cancer Research
9: 4296-4303.
Négrier, S., Fervers, B., Bailly, C., et al., 2001. Cutaneous Melanoma. British
Journal of Cancer 84(2): 81–85.
Paek, S.C., Sober, A.J., Tsao, H., et al., 2008. Cutaneous Melanoma. In: Wolff,
K., Goldsmith, L.A., Katz S.I., et al., 2008. Fitzpatrick’s Dermatology
in General Medicine, 7th ed. McGraw-Hill Companies: 1134-1149
Pasaribu, E.T., 2006. Kontroversi Profilaksis Elektif Node Diseksi dalam
Penanganan Melanoma Maligna. Majalah Kedokteran Nusantara
39(4): 433-436.
Putra, I.B., 2008. Tumor Kulit yang Berasal dari “Melanocytes System”. USU eRepository.
Rager, E.L., Bridgeford, E.P., and Ollila, D.W., 2005. Cutaneous Melanoma:
Update on Prevention, Screening, Diagnosis, and Treatment.
American Family Physician 72(2): 269-279.
Rao, U.M.N., Lee, S.J., Luo, W., et al., 2010. Presence of Tumor-Infiltrating
Lymphocytes and a Dominant Nodule Within Primary Melanoma Are
Prognostic Factors for Relapse-Free Survival of Patients With Thick
(T4) Primary Melanoma. Am J Clin Pathol 133: 646-653.
Reddy, S.S., Boukovalas, S., Barnica V., Zhu, F., et al., 2014. Tumor InfiltratingLymphocytes and Their Role as a Prognostic Indicator for Melanoma.
J Surgery 7(2): 01-07.
Siegel, R., Ma, J., Zou, Z., et al., 2014. Cancer Statistics, 2014. CA Cancer J Clin
64(1): 2-29.
Slingerland, J.M., Tannock, I.F., 1998. Cell Prolireation and Cell Death. In:
Tannock, I.F., Hill, R.P., 1998. The Basic Science of Oncology, 3rd ed.
The McGraw-Hill Companies: 134-145.
48
Spaner, D., Radvany, L., Miller, R.G., 1998. Immunology Related to Cancer. In:
Tannock, I.F., Hill, R.P., 1998. The Basic Science of Oncology, 3rd ed.
The McGraw-Hill Companies: 240-260.
Sukardja, I D.G., 2000. Onkologi Klinik, 2nd ed. Surabaya: Airlangga University
Press: 41-44.
Suyatno, Pasaribu, E.T., 2010. Bedah Onkologi Diagnosis dan Terapi. Jakarta:
Sagung Seto: 155-169.
Swetter, S.M., Geller, A.C., and Kirkwood, J.M., 2004. Melanoma in the Older
Person. Cancer Network.
Taylor, R.C., Patel, A., Panageas, K.S., et al., 2007. Tumor-infiltrating
Lymphocytes Predict Sentinel Lymph Node Positivity in Patients
With Cutaneous Melanoma. J Clin Oncol 25:869-875. DOI:
10.1200/JCO.2006.08.9755.
Teixeira, V., Vieira R., Coutinho I., et al., 2013. Prediction of Sentinel Node
Status and Clinical Outcome in a Melanoma Centre. Journal of Skin
Cancer . http://dx.doi.org/10.1155/2013/904701.
Thomas, N.E., Busam, K.J., From, L., et al., 2013. Tumor-Infiltrating
Lymphocyte Grade in Primary Melanomas Is Independently
Associated With Melanoma-Specific Survival in the Population-Based
Genes, Environment and Melanoma Study. Journal of Clinical
Oncology 31(33): 4252-4259.
Thompson, J.F., Soong, J., Balch, C.M., et al., 2011. Prognostic Significance of
Mitotic Rate in Localized Primary Cutaneous Melanoma: An
Analysis of Patients in the Multi-Institutional American Joint
Committee on Cancer Melanoma Staging Database. Journal of
Clinical Oncology 29(16): 2199-2205.
Vilanova, C.M.A., Ribeiro S.M., Lages R.B., et al., 2013. Epidemiological and
Histopathological Profile of Cutaneous Melanoma at a Centre in
49
Northeastern Brazil from 2000 to 2010. Anais Brasileiros de
Dermatologia . http://dx.doi.org/10.1590/abd1806-4841.20132036.
Zeng, G., 2001. MHC Class II-Restricted Tumor Antigens Recognized by CD4
Positive T Cells: New Strategies for Cancer Vaccine Design. In: Rao,
U.M.N., Lee, S.J., Luo, W., et al., 2010. Presence of TumorInfiltrating Lymphocytes and a Dominant Nodule Within Primary
Melanoma Are Prognostic Factors for Relapse-Free Survival of
Patients With Thick (T4) Primary Melanoma. Am J Clin Pathol 133:
646-653.
DAFTAR PUSTAKA
Attis, M.G., Vollmer, R.T., 2007. Mitotic Rate in Melanoma a Reexamination.
Am
J
Clin
Pathol
2007
127:380-384.
doi:
10.1309/LB7RTC61B7LC6HJ6.
Azimi, F., Scolyer, R.A., Rumcheva, P,. et al., 2012. Tumor-Infiltrating
Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph
Node Status and Survival in Patients with Cutaneous Melanoma.
Journal of Clinical Oncology 30(21): 2678-2683.
Balch, C.M., Gershenwald, J.E., Soong, S., et al., 2009. Final Version of 2009
AJCC Melanoma Staging and Classification. Journal of Clinical
Oncology 27(36): 6199-6206.
Balch, C.M., Gershenwald, J.E., Soong, S., et al., 2010. Multivariate Analysis of
Prognostic Factors Among 2,313 Patients With Stage III Melanoma:
Comparison of Nodal Micrometastases Versus Macrometastases.
Journal of Clinical Oncology 28(14): 2452-2459.
Bandarchi, B., Ma, L., Navab, R., et al., 2010. From Melanocyte to Metastatic
Malignant
Melanoma.
Dermatology
Research
and
Practice.
doi:10.1155/2010/583748
Bogunovic, D., O’Neill,D.W., Levy, I.B., et al., 2009. Immune Profile and
Mitotic Index of Metastatic Melanoma Lesions Enhance Clinical
Staging in Predicting Patient Survival. PNAS 106(48): 20429-20434.
Busam, K. J., Antonescu, C. R., Marghoob, A. A. et al., 2001. Histologi
Classification
of
Tumor-Infiltrating
Lymphocytes
in
Primary
Cutaneous Malignant Melanoma. Am J Clin Pathol 2001;115: 856860.
Chan, C., Greenbaum, A., 2013. Skin and Subcutaneous Tissue. In: Williams,
N.S., Bulstrode, C.J.K., O’Connel, P.R., 2013. Bailey & Love’s Short
Practice of Surgery, 26th ed. Boca Raton: Taylor & Francis Group,
CRC Press: 594-598.
44
Chung, K.T., Nilson, E.H., Case, M.J. et al., 1973. Estimation of Growth Rate
from the Mitotic Index. In: Thomas, N.E., Kricker, A., Waxweiler,
W.T. et al., 2014. Comparison of Clinicopathologic Features and
Survival
of
Histopathologically
Amelanotic
and
Pigmented
Melanomas: A Population-Based Study. JAMA Dermatol 150(12):
1306-1314.
de Vries, E., Bray, F., Coebergh, J.W., et al., 2006. Melanocytic tumours. In:
LeBoit, P.E., Burg, G., Weedon, D., et al., 2006. Pathology &
Genetics Skin Tumours. Lyon: International Agency for Research on
Cancer Press: 52-65.
de Vries, E., Nijsten, T.E.C., Visser, O., et al., 2007. Superior Survival of Females
Among 10 538 Dutch Melanoma Patients Is Independent of Breslow
Thickness, Histologic Type and Tumor Site. Annals of Oncology.
doi:10.1093/annonc/mdm498.
Donizy, P., Zietek, M., Leskiewicz, M., et al., 2015. High Percentage of ADAM10 Positive Melanoma Cells Correlates with Paucity of TumorInfiltrating Lymphocytes but Does Not Predict Prognosis in
Cutaneous Melanoma Patients. Analytical Cellular Pathology.
http://dx.doi.org/10.1155/2015/975436.
Forman, D., Bray, F., Brewster, D.H., et al., 2014. Cancer Incidence in Five
Continents vol. X. Lyon: International Agency for Research on
Cancer (164).
Garbe, C., Büttner, P., Bertz, J., et al., 1995. Primary Cutaneous Melanoma:
Prognostic
Classification
of
Anatomic
Location.
Cancer
1995(75):2492-8.
GLOBOCAN, 2012. Estimated Cancer Incidence, Mortality, and Prevalence
Worldwide in 2012. International Agency for Research on Cancer .
Available
at
45
http://globocan.iarc.fr/Pages/fact_sheets_population.aspx?country=36
0 [Accessed June 22th 2015]
Goldstein, B.G., and Goldstein, A.O., 2001. Diagnosis and Management of
Malignant Melanoma. American Family Physician 63(7): 1359-1386.
Hale, C.S., Qian, M., Ma, M.W. et al., 2013. Mitotic Rate in Melanoma:
Prognostic Value of Immunostaining and Computer-Assisted Image
Analysis. Am J Surg Pathol 37(6): 882–889.
Herbst, M.C., 2014. Fact Sheet on Malignant Melanoma. Cancer Association of
South Africa : 1-15.
Hernberg, M., Turunen, J.P., Muhonen, T. et al., 1997. Tumor Infiltrating
Lymphocytes
in
Metastatic
Melanomas
Receiving
Chemoimmunotherapy. In: Rao, U.M.N., Lee, S.J., Luo, W., et al.,
2010. Presence of Tumor-Infiltrating Lymphocytes and a Dominant
Nodule Within Primary Melanoma Are Prognostic Factors for
Relapse-Free Survival of Patients With Thick (T4) Primary
Melanoma. Am J Clin Pathol 133: 646-653.
Holterhues, C., 2011. Burden of Melanoma. Rotterdam: Optima Grafische
Communicatie: 7-10.
Houghton, A.N., Guevara-patiño, J.A., 2004. Immune Recognition of Self in
Immunity Against Cancer. J. Clin. Invest. 114: 468–471 (2004).
doi:10.1172/JCI200422685.
Junowo, Juniarto, A.Z., 2000. Biologi Sel. Jakarta: Penerbit Buku Kedokteran
EGC: 75-83.
King, R.J.B., 2000. Cancer Biology, 2nd ed. Pearson Education Limited: 58-68,
148-157.
Knezevich, S.R., Barnhill, R.L., Elder, D.E., et al., 2014. Variability in Mitotic
Figures in Serial Sections of Thin Melanomas. American Academy of
Dermatology. J Am Acad Dermatol 71(6): 1204–1211.
46
Larsen, T.E., Grude, T.H., 1978. A Retrospective Histological Study of 669 Cases
of Primary Cutaneous Malignant Melanoma in Clinical Stage I: 3, The
Relationship Between the Tumor-Associated Lymphocyte Infiltration
and Age and Sex, Tumor Cell Type, Pigmentation, Cellular Atypia,
Mitotic Count, Depth of Invasion, Ulceration, Tumor Type and
Prognosis. In: Taylor, R.C., Patel, A., Panageas, K.S., et al., 2007.
Tumor-infiltrating Lymphocytes Predict Sentinel Lymph Node
Positivity in Patients With Cutaneous Melanoma. J Clin Oncol
25:869-875. DOI: 10.1200/JCO.2006.08.9755.
Lee, S.J., Lim, H.J., Choi, Y.H., et al., 2013. The Clinical Significance of TumorInfiltrating Lymphocytes and Microscopic Satellites in Acral
Melanoma in a Korean Population. Ann Dermatol 25(1):61-66.
http://dx.doi.org/10.5021/ad.2013.25.1.61.
Ma, M.W., Medicherla, R.C., Qian, M., et al., 2012. Immune Response in
Melanoma: an In-Depth Analysis of The Primary Tumor and
Corresponding Sentinel Lymph Node. National Institute of Health.
doi:10.1038/modpathol.2012.43.
MacKie, R.M., Hauschild, A., and Eggermont, A.M.M., 2009. Epidemiology of
Invasive Cutaneous Melanoma. Annals of Oncology 20(6): vi1–vi7.
Maio, M., 2012. Melanoma as a Model Tumour for Immuno-Oncology. Annals of
Oncology 23 (Supplement 8): viii 10. doi:10.1093/annonc/mds257.
McCourt, C., Dolaé, O., and Gormley, G., 2014. Malignant Melanoma: A
Pictorial Review. Ulster Med J 83(2): 103-110.
Miller, A.J., and Mihm, M.C., 2006. Mechanisms of Disease Melanoma. N Engl J
Med 355: 51-65.
Nagore, E., Oliver, V., Botella-Estrada, R., et al., 2006. Clinicophatological
Analysis of 1571 Cutaneous Malignant Melanoma in Valencia, Spain:
Factors Related to Tumour Thickness. Acta Derm Venerol 2006
(86):50-56. DOI: 10.2340/00015555-0004.
47
Nagorsen, D., Scheibenbogen, C., Marincola, F.M., et al., 2003. Natural T Cell
Immunity Against Cancer. American Association for Cancer Research
9: 4296-4303.
Négrier, S., Fervers, B., Bailly, C., et al., 2001. Cutaneous Melanoma. British
Journal of Cancer 84(2): 81–85.
Paek, S.C., Sober, A.J., Tsao, H., et al., 2008. Cutaneous Melanoma. In: Wolff,
K., Goldsmith, L.A., Katz S.I., et al., 2008. Fitzpatrick’s Dermatology
in General Medicine, 7th ed. McGraw-Hill Companies: 1134-1149
Pasaribu, E.T., 2006. Kontroversi Profilaksis Elektif Node Diseksi dalam
Penanganan Melanoma Maligna. Majalah Kedokteran Nusantara
39(4): 433-436.
Putra, I.B., 2008. Tumor Kulit yang Berasal dari “Melanocytes System”. USU eRepository.
Rager, E.L., Bridgeford, E.P., and Ollila, D.W., 2005. Cutaneous Melanoma:
Update on Prevention, Screening, Diagnosis, and Treatment.
American Family Physician 72(2): 269-279.
Rao, U.M.N., Lee, S.J., Luo, W., et al., 2010. Presence of Tumor-Infiltrating
Lymphocytes and a Dominant Nodule Within Primary Melanoma Are
Prognostic Factors for Relapse-Free Survival of Patients With Thick
(T4) Primary Melanoma. Am J Clin Pathol 133: 646-653.
Reddy, S.S., Boukovalas, S., Barnica V., Zhu, F., et al., 2014. Tumor InfiltratingLymphocytes and Their Role as a Prognostic Indicator for Melanoma.
J Surgery 7(2): 01-07.
Siegel, R., Ma, J., Zou, Z., et al., 2014. Cancer Statistics, 2014. CA Cancer J Clin
64(1): 2-29.
Slingerland, J.M., Tannock, I.F., 1998. Cell Prolireation and Cell Death. In:
Tannock, I.F., Hill, R.P., 1998. The Basic Science of Oncology, 3rd ed.
The McGraw-Hill Companies: 134-145.
48
Spaner, D., Radvany, L., Miller, R.G., 1998. Immunology Related to Cancer. In:
Tannock, I.F., Hill, R.P., 1998. The Basic Science of Oncology, 3rd ed.
The McGraw-Hill Companies: 240-260.
Sukardja, I D.G., 2000. Onkologi Klinik, 2nd ed. Surabaya: Airlangga University
Press: 41-44.
Suyatno, Pasaribu, E.T., 2010. Bedah Onkologi Diagnosis dan Terapi. Jakarta:
Sagung Seto: 155-169.
Swetter, S.M., Geller, A.C., and Kirkwood, J.M., 2004. Melanoma in the Older
Person. Cancer Network.
Taylor, R.C., Patel, A., Panageas, K.S., et al., 2007. Tumor-infiltrating
Lymphocytes Predict Sentinel Lymph Node Positivity in Patients
With Cutaneous Melanoma. J Clin Oncol 25:869-875. DOI:
10.1200/JCO.2006.08.9755.
Teixeira, V., Vieira R., Coutinho I., et al., 2013. Prediction of Sentinel Node
Status and Clinical Outcome in a Melanoma Centre. Journal of Skin
Cancer . http://dx.doi.org/10.1155/2013/904701.
Thomas, N.E., Busam, K.J., From, L., et al., 2013. Tumor-Infiltrating
Lymphocyte Grade in Primary Melanomas Is Independently
Associated With Melanoma-Specific Survival in the Population-Based
Genes, Environment and Melanoma Study. Journal of Clinical
Oncology 31(33): 4252-4259.
Thompson, J.F., Soong, J., Balch, C.M., et al., 2011. Prognostic Significance of
Mitotic Rate in Localized Primary Cutaneous Melanoma: An
Analysis of Patients in the Multi-Institutional American Joint
Committee on Cancer Melanoma Staging Database. Journal of
Clinical Oncology 29(16): 2199-2205.
Vilanova, C.M.A., Ribeiro S.M., Lages R.B., et al., 2013. Epidemiological and
Histopathological Profile of Cutaneous Melanoma at a Centre in
49
Northeastern Brazil from 2000 to 2010. Anais Brasileiros de
Dermatologia . http://dx.doi.org/10.1590/abd1806-4841.20132036.
Zeng, G., 2001. MHC Class II-Restricted Tumor Antigens Recognized by CD4
Positive T Cells: New Strategies for Cancer Vaccine Design. In: Rao,
U.M.N., Lee, S.J., Luo, W., et al., 2010. Presence of TumorInfiltrating Lymphocytes and a Dominant Nodule Within Primary
Melanoma Are Prognostic Factors for Relapse-Free Survival of
Patients With Thick (T4) Primary Melanoma. Am J Clin Pathol 133:
646-653.